Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) price on Thursday, August 26, fall -5.63% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.57.
A look at the stock’s price movement, the close in the last trading session was $0.61, moving within a range at $0.568 and $0.6088. Turning to its 52-week performance, $3.41 and $0.60 were the 52-week high and 52-week low respectively. Overall, SONN moved -48.98% over the past month.
Sonnet BioTherapeutics Holdings Inc.’s market cap currently stands at around $27.53 million, with investors looking forward to this quarter’s earnings report slated for Aug 12, 2021 – Aug 16, 2021.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that SONN is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend SONN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SONN’s current price about -39.10% and -51.88% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.96, while 7-day volatility ratio is 7.30% and 11.55% in the 30-day chart. Further, Sonnet BioTherapeutics Holdings Inc. (SONN) has a beta value of 0.63, and an average true range (ATR) of 0.16. Analysts have given the company’s stock an average 52-week price target of $8.00, forecast between a low of $8.00 and high of $8.00. Looking at the price targets, the low is -1303.51% off current price level while to achieve the yearly target high, price needs to move -1303.51%. Nonetheless, investors will most likely welcome a -1303.51% jump to $8.00 which is the analysts’ median price.
In the market, a comparison of Sonnet BioTherapeutics Holdings Inc. (SONN) and its peers suggest the former has performed considerably weaker. Data shows SONN’s intraday price has changed -5.63% in last session and -80.83% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.58% and -0.54% respectively in the last trading.
If we refocus on Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN), historical trading data shows that trading volumes averaged 46.55 million over the past 10 days and 5.55 million over the past 3 months. The company’s latest data on shares outstanding shows there are 48.18 million shares.
The 3.20% of Sonnet BioTherapeutics Holdings Inc.’s shares are in the hands of company insiders while institutional holders own 4.50% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.53 million on May 27, 2021, giving us a short ratio of 0.3. The data shows that as of May 27, 2021 short interest in Sonnet BioTherapeutics Holdings Inc. (SONN) stood at 2.46% of shares outstanding, with shares short rising to 0.29 million registered in Apr 29, 2021. Current price change has pushed the stock -74.38% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SONN stock continues to rise going into the next quarter.